Related Party Transactions - Additional Information (Detail) - USD ($) |
1 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 13, 2015 |
Oct. 03, 2014 |
Oct. 31, 2016 |
Sep. 30, 2016 |
Jul. 31, 2016 |
Jul. 26, 2016 |
May 31, 2016 |
Apr. 27, 2016 |
Oct. 31, 2015 |
May 31, 2015 |
Mar. 20, 2015 |
Mar. 17, 2015 |
Feb. 17, 2015 |
Sep. 30, 2014 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2012 |
Sep. 09, 2016 |
Jul. 05, 2016 |
Mar. 17, 2014 |
|
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Costs and Expenses, Related Party | $ 84,000 | $ 24,000 | $ 100,000 | ||||||||||||||||||
| Accounts Receivable, Net, Total | 71,800 | ||||||||||||||||||||
| Agreement Description Terms | (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). | (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Cellvation or any of its respective subsidiaries that occurs after the effective date of the Cellvation Founders Agreement and ending on the date when the Company no longer has majority voting control in Cellvations voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Cellvations annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Cellvation will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). | (i) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Helocyte Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Helocyte’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). | (i) issue annually to the Company, on the anniversary date of the Checkpoint Founders Agreement, shares of common stock equal to 2.5% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Checkpoint Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Checkpoint Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). | (i) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Avenue Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). | ||||||||||||||||
| Operating Leases, Rent Expense | $ 2,700,000 | $ 53,000 | $ 200,000 | $ 0.1 | |||||||||||||||||
| Lease Sharing Agreements Contributions To Property Under Lease | 4,800,000 | ||||||||||||||||||||
| Business Combination, Consideration Transferred | $ 22,872,000 | ||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 35.00% | ||||||||||||||||||||
| National Holdings Corporation [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Business Acquisition, Percentage of Voting Interests Acquired | 56.10% | 56.00% | 56.60% | ||||||||||||||||||
| Business Combination, Consideration Transferred | $ 22,900,000 | $ 22,900,000 | |||||||||||||||||||
| Proceeds from Fees Received | $ 1,300,000 | ||||||||||||||||||||
| NSC Note [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Long-term Debt, Gross | $ 3,600,000 | ||||||||||||||||||||
| Chief Executive Officer [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Interest own in percent by principal stockholder or director | 12.30% | 12.20% | 12.40% | ||||||||||||||||||
| Chord Advisors, LLC [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Related Party Transaction, Expenses from Transactions with Related Party | $ 10,000 | ||||||||||||||||||||
| Board of Directors Chairman [Member] | National Holdings Corporation [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 4.60% | ||||||||||||||||||||
| TG Therapeutics, Inc [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Percentage of Rentable Area | 45.00% | 40.00% | |||||||||||||||||||
| Operating Leases, Rent Expense | $ 1,100,000 | ||||||||||||||||||||
| Lease Improvement Cost Associate With Lease | $ 5,100,000 | ||||||||||||||||||||
| Due from Related Parties, Current | 2,100,000 | ||||||||||||||||||||
| Prepaid Rent | 400,000 | ||||||||||||||||||||
| OPPM [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Percentage of Rentable Area | 10.00% | 20.00% | |||||||||||||||||||
| Operating Leases, Rent Expense | $ 500,000 | ||||||||||||||||||||
| Lease Improvement Cost Associate With Lease | 5,100,000 | ||||||||||||||||||||
| Due from Related Parties, Current | 500,000 | ||||||||||||||||||||
| Prepaid Rent | 95,000 | ||||||||||||||||||||
| Executives Vice Chairman [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Interest own in percent by family members of principal stockholder or director | 14.90% | ||||||||||||||||||||
| Mustang [Member] | Chord Advisors, LLC [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Related Party Transaction, Expenses from Transactions with Related Party | $ 7,500 | ||||||||||||||||||||
| Founder [Member] | Founders Agreement [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Lessee Leasing Arrangements, Operating Leases, Term of Contract | 15 years | ||||||||||||||||||||
| Management Services Agreement [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Annual Consulting Fee | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | |||||||||||||||||
| Increase in Annual Consulting Fee | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||
| Excess In Net Assets Value | $ 100,000,000 | $ 100,000,000 | 100,000,000 | $ 100,000,000 | |||||||||||||||||
| Management Services Agreement [Member] | Checkpoint [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Long-term Debt, Gross | $ 2,800,000 | ||||||||||||||||||||
| Avenue [Member] | Chord Advisors, LLC [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Related Party Transaction, Expenses from Transactions with Related Party | $ 5,000 | ||||||||||||||||||||
| Avenue [Member] | Founders Agreement [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Agreement Description Terms | Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class B Common shares for 6.75 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Helocyte common stock and (B) the whole shares of Helocyte common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Helocyte common stock, subject to certain adjustments. As the sole holder of Class A Preferred Stock, the Company will receive on each March 20 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Helocyte’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. | Company entered into a Founders Agreement with Avenue, which was amended and restated on September 13, 2016 (the “Avenue Founders Agreement”), pursuant to which the Company assigned to Avenue all of its rights and interest under the Company’s license agreement with Revogenex for IV Tramadol. As consideration for the Avenue Founders Agreement, Avenue assumed $3.0 million in debt that the Company accumulated under the NSC Note (see Note 11) for expenses and costs of forming Avenue and obtaining IV Tramadol license, of which $3.0 million represents the acquisition of the License Agreement. The Avenue Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Avenue Founders Agreement) occurs. Concurrently with the amendment and restatement of the Avenue Founders Agreement, the Company entered into an Exchange Agreement whereby the Company exchanged its 7.0 million Class A Common shares for approximately 7.5 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights, election of directors and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Avenue common stock and (B) the whole shares of Avenue common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at its option, into one fully paid and nonassessable share of Avenue common stock, subject to certain adjustments. For a period of 10 years from the date of the first issuance of Class A Preferred Stock, the holders of record of shares of Class A Preferred Stock, exclusively and as a separate class, are entitled to appoint or elect the majority of Avenue’s Board of Directors. As holders of Class A Preferred Stock, the Company will receive on each February 17 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Avenue’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. | |||||||||||||||||||
| Desk Share Agreements [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Payments for Rent | 1,000,000 | ||||||||||||||||||||
| Mustang Bio, Inc [Member] | Founders Agreement [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Lessee Leasing Arrangements, Operating Leases, Term of Contract | 15 years | ||||||||||||||||||||
| Agreement Description Terms | Concurrently with the second amendment to the Mustang Founders Agreement, the Company entered into an Exchange Agreement whereby the Company exchanged its 7.25 million Class B Common shares for 7.0 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A Common Stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at the Company’s option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, the Company will receive on each March 13 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustang’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. | ||||||||||||||||||||
| Cellvation [Member] | Founders Agreement [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Agreement Description Terms | Company entered into a Founders Agreement with Cellvation (the “Cellvation Founders Agreement”). The Cellvation Founders Agreement provides that, in exchange for the time and capital expended in the formation of Cellvation and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, the Company will loan Cellvation $0.2 million, representing the up-front fee required to acquire Cellvation’s license agreement and continue to fund Cellvation’s working capital needs. The Cellvation Founders Agreement has a term of 15 years, which, upon expiration, automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Cellvation Founders Agreement) occurs. Pursuant to the Cellvation Founders Agreement, the Company received 7.6 million common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Cellvation common stock and (B) the whole shares of Cellvation common stock into which the shares of outstanding Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at the Company’s option, into one fully paid and nonassessable share of Cellvation common stock, subject to certain adjustments. As holders of Class A Preferred Stock, the Company will receive on each October 31 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Cellvation’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. | ||||||||||||||||||||
| Shared Services Agreement [Member] | TG Therapeutics, Inc [Member] | |||||||||||||||||||||
| Related Party Transaction [Line Items] | |||||||||||||||||||||
| Proceeds from Related Party Agreement | $ 800,000 | ||||||||||||||||||||